Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 study of IVIG (GGS) in CIDP
jRCT2080222421Phase 3Completed
- Sponsor
- Teijin Pharma
- Start
- Mar 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of subcuvia in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Teijin Pharma. Primary endpoint: Responder rate based on total adjusted INCAT score at 3 weeks. Started Mar 2014; status: completed.
02
Drugs
subcuvia
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2080222421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222421.